PCSK9 and Alzheimer disease: Potential effects of PCSK9 inhibitors on plasma amyloid homeostasis are not known, but to the contrary, on the basis that cognitive impairment in AD is associated with cholesterol metabolism, PCSK inhibitors are presently issued with a warning concerning possible negative impact on cognitive function.